---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-013196"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T03:22:37.055102+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Telomir Pharmaceuticals announces BIO 2025 participation and preclinical progress for Telomir-1

## Summary
- Telomir will participate in the BIO International Convention 2025 in Boston from June 16-19, 2025, with scheduled partnering meetings.
- The company plans to submit an IND by year-end and initiate first-in-human clinical trials in the first half of 2026.
- Preclinical data showed retinal regeneration in AMD, lifespan extension in Progeria/Werner's, reversal of Type 2 diabetes parameters, and ~50% tumor reduction in prostate cancer model.
- Telomir launched a rare disease initiative targeting Werner's, Wilson's, Progeria, and dysphonia, and introduced Telomir-Ag2 for multidrug-resistant bacteria including MRSA.

## SEC filing metadata
- accession: 0001641172-25-013196
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000164117225013196/0001641172-25-013196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000164117225013196/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-013196
- JSON: https://secwatch.observer/filing/0001641172-25-013196.json
- Plain text: https://secwatch.observer/filing/0001641172-25-013196.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.